A Randomized Phase IIa Study of TAS-205 in Patients With Duchenne Muscular Dystrophy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2017
At a glance
- Drugs TAS 205 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 07 Jun 2017 Biomarkers information updated
- 26 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 10 May 2016 Status changed from not yet recruiting to recruiting.